Oncolytics Biotech (@Oncolytics) header
Oncolytics Biotech (@Oncolytics) profile picture

Oncolytics is developing pelareorep, an IV delivered I-O agent, which introduces double-stranded RNA into cancer cells. Contact company: https://teapawt.net/t.co/sNAsxxiOi5

San Diego, California
Joined March 2009
Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)Photo by Oncolytics Biotech (@Oncolytics)
The clinical supply agreement announced today enables us to advance our #AnalCancer program with the opportunity to evaluate #pelareorep as a potential treatment for multiple HPV-driven tumors. Learn more in the PR: ir.oncolyticsbiotech.com/pre… #biotech #Oncology #immunotherapy
3
215
Translational data presented at #ASH26 show #pelareorep activates both antiviral and antitumor immune pathways in heavily pretreated relapsed/refractory multiple myeloma patients, including enhanced antigen presentation and expansion of CD8 EM T cells: ir.oncolyticsbiotech.com/pre…
1
1
1
250
At #SITC26 we’re presenting new translational data showing #pelareorep activates anti-tumor immunity in #AnalCancer patients. These findings support its potential as a backbone immunotherapy across multiple HPV-driven cancers. Link to the PR: ir.oncolyticsbiotech.com/pre… #SITC2026
1
173
Updated #AnalCancer data show median OS has not yet been reached, but all responding patients survived beyond 12 months and median DOR is ~15 months, which compares favorably to historical benchmarks. More on this and the HPV strategy for #pelareorep here: ir.oncolyticsbiotech.com/pre…
1
183
At #ESMO26 we will highlight our randomized, controlled REO 033 #ColorectalCancer study. It is designed to validate previous efficacy signals showing #pelareorep + standard of care more than doubled historical benchmarks. Learn more in the PR: ir.oncolyticsbiotech.com/pre… #ESMO2026
1
3
212
Data from the GOBLET study has been critical for the development of #pelareorep. @PanCAN helped fund Cohort 5 of GOBLET, and we are now expecting a final grant payment by year-end. We thank them for their efforts and look forward to upcoming milestones: ir.oncolyticsbiotech.com/pre…
2
198
We continue to expand patent protection for #pelareorep into the late 2040s through a newly issued method of use patent, 3 patent application families pending, and development of a potential composition of matter patent to support "next generation" pela: ir.oncolyticsbiotech.com/pre…
5
390
We believe #pelareorep can be a backbone immunotherapy. An academic paper shows pela transforms the TME to be immunologically active in liver cancer, which is notoriously challenging. This can enable immunotherapies like checkpoint inhibitors to work: ir.oncolyticsbiotech.com/pre…
1
2
252
Nearly all of our planned sites for the REO 033 #ColorectalCancer study are now open. Enrollment is accelerating, and we anticipate having interim data to report by year-end, which will be critical as we consider the potential pivotal Part B expansion: ir.oncolyticsbiotech.com/pre…
2
6
243
#RAS inhibitors are one of the most important emerging classes of cancer therapy. Today, we show pelareorep can reduce tumor growth alone and in combination with a pan-RAS inhibitor compared to a control in a preclinical RAS-driven colorectal cancer model: ir.oncolyticsbiotech.com/pre…
2
251
As a result of FDA’s written feedback and alignment on our REO 033 #ColorectalCancer study, we will forgo a Type D meeting and will pursue an End-of-Phase meeting. Notably, a Part B expansion could support accelerated approval based on ORR and DOR: ir.oncolyticsbiotech.com/pre…
2
338
Where could pelareorep go next? Today, we’re focused on GI tumors, where unmet need is high and data is building. Biology suggests the potential doesn’t stop there. Full @ZacksSmallCap interview: scr.zacks.com/news/news-deta…
6
433
Oncolytics Biotech retweeted
Jared Kelly, CEO of Oncolytics Biotech Inc. (ONCY), joins WTR Healthcare Happenings in this episode for a discussion on the company's progress advancing pelareorep, its investigational oncolytic virus immunotherapy for difficult-to-treat gastrointestinal cancers. - The significant unmet need in RAS-mutated colorectal, pancreatic, and anal cancers — tumor types largely left behind by immunotherapy advances - How pelareorep's systemically delivered mechanism selectively targets tumor cells while stimulating an anti-cancer immune response - Recent clinical results, upcoming data readouts, regulatory progress, and Oncolytics' strategy for registration-directed colorectal cancer studies and partnerships Listen here on all platforms or website: Platforms: pod.link/1795488592 Website: watertowerresearch.com/media… $ONCY #Oncolytics #Pelareorep #GastrointestinalCancer #ColorectalCancer #PancreaticCancer #Immunotherapy #OncolyticVirus #Biotech #ClinicalTrials #Oncology #DrugDevelopment #HealthcareInvesting #SmallCap #WTR @Oncolytics
3
1
315
The FDA has granted Fast Track designation to pelareorep in advanced anal cancer, supporting development for patients with no approved options after first‑line therapy. This marks its third Fast Track designation in GI cancers. 🔗 Read more: ir.oncolyticsbiotech.com/pre…
1
3
720
CEO Jared Kelly highlights the challenges and opportunities biotechs face designing clinical trials that maintain investor engagement while pursuing overall survival + how #pelareorep and oncolytic viruses may offer unique advantages in cancer treatment: biopharminternational.com/vi…
1
2
247
When immunotherapy fails, the drug isn't always the problem. Often it comes down to getting the drug to the tumor. Dr. Richard Vile discusses our work to trigger a powerful immune response directly within the tumor microenvironment. More on @endpts: webinars.endpoints.news/from…
1
19
27
480
Our REO 033 #ColorectalCancer study is expected to have half of the planned clinical sites activated by the end of this month and we are scheduled to meet with the FDA to discuss a pathway that supports both potential accelerated and full approval: ir.oncolyticsbiotech.com/pre…
18
30
304
In metastatic colorectal cancer, traditional immunotherapies often hit a wall because the immune system can't get past the front door. Dr. Van Morris breaks down how a novel approach could change the game from the inside out. Full @endpts webinar: webinars.endpoints.news/from…
263
Patent protection for #pelareorep has been extended into 2044 with the granting of a new patent covering its manufacturing process. Intellectual property is a cornerstone of pelareorep’s development, and we have or will file more patents. Here is the PR: ir.oncolyticsbiotech.com/pre…
2
208
We have appointed Steve Glover to the Oncolytics Board and promoted John McAdory to Chief Operating Officer. Both will play crucial roles as we position #pelareorep as an immunotherapy backbone for #GastrointestinalCancer patients. Read the PR here: ir.oncolyticsbiotech.com/pre…
228